KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查 入排置信度 0.96

Nasal biomarker inflammatory profile in response to intranasal corticosteroids in pediatric obstructive sleep apnea syndrome.

Ambika G Chidambaram, Christopher M Cielo, Inna Chervoneva, Jonathan M Spergel, Ignacio E Tapia

J Clin Sleep Med 21(6) 1033-1040

PMID40051199
PMCIDPMC12134589
DOI10.5664/jcsm.11604
发表日期2025-03-07
入排依据:属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
摘要

摘要

STUDY OBJECTIVES: Nasopharyngeal inflammation contributes to pediatric obstructive sleep apnea syndrome (OSAS). Intranasal corticosteroids (INCS) are used to treat pediatric OSAS; a randomized controlled trial showed an improvement in OSAS symptoms but without polysomnography or neurobehavioral outcome differences. There is a lack of data demonstrating an objective decrease in the nasal inflammatory biomarker profile associated with INCS. Hence, we evaluated the association of nasal inflammatory biomarker profile and response to INCS. METHODS: Secondary analysis of a randomized controlled trial of INCS vs placebo in pediatric OSAS (n = 134). The difference in intranasal biomarkers (interleukin (IL)-4, IL-13, tumor necrosis factor-alpha) between the groups after 3 and 12 months was evaluated. The association of the nasal inflammatory biomarker profile and response to INCS was assessed. Multiple regression analysis was performed to identify clinical predictors of response to INCS. RESULTS: There were no statistically significant differences in the nasal IL-4, IL-13, and tumor necrosis factor-alpha levels between INCS and placebo groups after 3 and 12 months of treatment. Within the INCS group, there was no statistically significant change in the nasal IL-4, IL-13, and tumor necrosis factor-alpha levels after 3 months of therapy based on responder status. However, among those who received INCS, obesity and a higher obstructive apnea-hypopnea index at baseline were clinical predictors of greater obstructive apnea-hypopnea index after 3 months (P = .038 and .002, respectively). CONCLUSIONS: INCS did not affect the nasal inflammatory biomarker profile in children with OSAS, including the responders. In addition, INCS is not recommended as a treatment option in children with obesity or high obstructive apnea-hypopnea index at baseline. CLINICAL TRIAL REGISTRATION: Registry: ClinicalTrials.gov; Name: Steroids for Pediatric Apnea Research in Kids (SPARK); URL: https://clinicaltrials.gov/study/NCT02180672; Identifier: NCT02180672. CITATION: Chidambaram AG, Cielo CM, Chervoneva I, Spergel JM, Tapia IE. Nasal biomarker inflammatory profile in response to intranasal corticosteroids in pediatric obstructive sleep apnea syndrome. J Clin Sleep Med. 2025;21(6):1033-1040.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。